James Brian Byrd

Latest

• Pandemic pandemonium: pausing clinical research during the COVID-19 outbreak
• Angiotensin receptor blockers and the risk of cancer: insights from clinical trials and recent drug recalls
• Current status of angiotensin receptor blocker recalls
• Medicare reimbursement policy for ambulatory blood pressure monitoring: a qualitative analysis of public comments to the Centers for Medicare and Medicaid Services
• Privacy-preserving generative deep neural networks support clinical data sharing
• Hypertension
• Hypertension hot potato — anatomy of the angiotensin-receptor blocker recalls
• Score one for the clinical trial data sharing experiment
• For what factors should we normalize urinary extracellular mRNA biomarkers?
• Strengthening a societal tie and other new initiatives for 2019
• Personalized medicine and the treatment of hypertension
• Adrenal vein sampling lateralization despite mineralocorticoid receptor antagonists exposure in primary aldosteronism
• Privacy-preserving generative deep neural networks support clinical data sharing
• Minimal information for studies of extracellular vesicles 2018 (MISEV2018), a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines
• Monitoring blood pressure outside of the doctor's office
• Out-of-office blood pressure monitoring in 2018
• Clinical research using extracellular vesicles, insights from the International Society for Extracellular Vesicles 2018 Annual Meeting
• Human urinary mRNA as a biomarker of cardiovascular disease
• Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial
• Primary aldosteronism
• Opening opportunities with open data
• Summary of the ISEV workshop on extracellular vesicles as disease biomarkers, held in Birmingham, UK, during December 2017
• Countries’ geographic latitude and their human populations’ cholesterol and blood pressure
• Pharmacologic treatment of hypertension
• Use of physician-recommended non-pharmacological strategies for hypertension control among hypertensive patients
• Discordance between imaging and immunohistochemistry in unilateral primary aldosteronism
• Data-sharing models
• Reach Out Churches, a community-based participatory research pilot trial to assess the feasibility of a mobile health technology intervention to reduce blood pressure among African Americans
• Cigarette smoking and subtypes of uncontrolled blood pressure among diagnosed hypertensive patients: paradoxical associations and implications
• Hypertension: from pre-hypertension to heart failure
• Alternative approaches for lowering blood pressure
• EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research
• Primary aldosteronism in the primary care clinic: rife or rare?
• Personalized medicine and treatment approaches in hypertension: current perspectives
• Acute increase in blood pressure during inhalation of coarse particulate matter air pollution from an urban location
• Hypertension section (within Cardiovascular medicine chapter)
• Serum cortisol-to-cortisone ratio and blood pressure in severe obesity before and after weight loss
• Aldosterone synthase promoter polymorphism and cardiovascular phenotypes in a large, multiethnic population-based study
• Resistance to recommending exercise in hypertension?
• Anxiety in the "age of hypertension"
• Clopidogrel prescription filling delays and cardiovascular outcomes in a pharmacy system integrating inpatient and outpatient care: insights from the Veterans Affairs CART Program
• Arm position during ambulatory blood pressure monitoring: a review of the evidence and clinical guidelines
• The contribution of the ACCOMPLISH trial to the treatment of stage 2 hypertension
• A critical review of the evidence supporting aldosterone in the etiology and its blockade in the treatment of obesity-associated hypertension
• Pollen count and presentation of angiotensin-converting enzyme inhibitor-associated angioedema
• Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema
• Data quality of an electronic health record tool to support VA cardiac catheterization laboratory quality improvement: the VA Clinical Assessment, Reporting, and Tracking System for Cath Labs (CART) program
• Detection and recognition of hypertension in anxious and depressed patients
• The possibility of unmeasured confounding variables in observational studies: a forgotten fact?
• Combination therapy as initial treatment for newly diagnosed hypertension
• Pericardial effusion in renal disease: to tap or not to tap
• Association of angiotensin-converting enzyme inhibitor-associated angioedema with transplant and immunosuppressant use
• Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema
• Les effets secondaires aigus des inhibiteurs de l’enzyme de conversion de l’angiotensine dont l’angioœdème, différents dans leur étiologie clinique, partagent une physiopathologie semblable
• Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition
• Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema
• Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema
• Angiotensin-converting enzyme inhibitor-associated angioedema